{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:26:00Z","timestamp":1787304360844,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Sin\u00fa"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>First-line drug treatment is the cornerstone of glaucoma management. However, their adverse effects on the ocular surface have led to multiple retrospective studies in previously treated patients. This study evaluated these effects in patients who had never been exposed to these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the effect of first-line drugs for the management of primary open-angle glaucoma and ocular hypertension on the cornea over one year of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational, longitudinal, and prospective study of patients from the Colombian Caribbean coast with no prior treatment or ocular alterations. The patients were evaluated with the OCT-Cirrus 6000, the Ocular Surface Analyzer (OSA), and the OSDI survey at one-year follow-up. The statistical analysis was performed using the Epi Info v.7.2 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 88 eyes of 44 patients with an average age of 62.9\u00a0years were analyzed. Total corneal thickness (TCT) decreased from 537.6 to 533.8\u00a0\u00b5m, with no statistical significance, and total epithelial thickness (TET) decreased from 45.6 to 43.9\u00a0\u00b5m, a statistically significant difference. The OSDI survey increased from 7.3 to 13.4. The OSA showed a reduction in BUT from 8.3 to 6.9\u00a0s, the lipid layer from 3.8 to 3.0\u00a0nm, the tear meniscus height from 0.37 to 0.29\u00a0mm, and meibomian gland loss increased 12.6% at 1-year follow-up; all of these parameters were statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings reveal that antiglaucoma medications induce alterations in the ocular surface and cornea, and suggest that the greater the involvement of the corneal epithelium, the greater the symptoms reported by the patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-026-04205-5","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:46:39Z","timestamp":1787301999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of first-line topical medications for the treatment of glaucoma on the ocular surface in a Latin American population"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-5438","authenticated-orcid":false,"given":"Oscar Luis","family":"Teher\u00e1n Forero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6972-052X","authenticated-orcid":false,"given":"Liliana Mar\u00eda","family":"Hoyos C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6927-5924","authenticated-orcid":false,"given":"Cristina Isabel","family":"Balmaceda Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8650-2064","authenticated-orcid":false,"given":"Stella","family":"Ortega Buelvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-5800","authenticated-orcid":false,"given":"Enrique","family":"Ramos Clason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"#cr-split#-4205_CR1.1","unstructured":"World Health Organization (2025) Blindness and vision impairment [Internet]. Geneva: WHO"},{"key":"#cr-split#-4205_CR1.2","unstructured":"[cited 2025 Jun 14]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"key":"4205_CR2","volume-title":"Terminology and guidelines for glaucoma","author":"European Glaucoma Society","year":"2020","unstructured":"European Glaucoma Society (2020) Terminology and guidelines for glaucoma, 4th ed. PubliComm, Savona (Italy)","edition":"4th ed"},{"key":"4205_CR3","unstructured":"American Academy of Ophthalmology. (2020) Primary open-angle glaucoma Preferred Practice Pattern\u00ae guidelines. San Francisco (CA): AAO; Developed by the AAO PPP glaucoma committee, Hoskins center for quality eye care"},{"key":"4205_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120901698","author":"E Do\u011fan","year":"2020","unstructured":"Do\u011fan E, K\u00f6kl\u00fc \u00c7ak\u0131r B, \u00d6zkan Aksoy N, Celik E, Erkorkmaz \u00dc (2020) Effects of topical antiglaucomatous medications on central corneal epithelial thickness by anterior segment optical coherence tomography. Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/1120672120901698","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"4205_CR5","doi-asserted-by":"publisher","first-page":"e201900095","DOI":"10.1002\/jbio.201900095","volume":"13","author":"D Montorio","year":"2020","unstructured":"Montorio D, Cennamo G, Breve MA, Fiore U, Reibaldi M, Brescia Morra V (2020) Evaluation of corneal epithelial thickness in glaucomatous patients using anterior-segment optical coherence tomography. J Biophotonics 13(1):e201900095. https:\/\/doi.org\/10.1002\/jbio.201900095","journal-title":"J Biophotonics"},{"key":"4205_CR6","doi-asserted-by":"publisher","unstructured":"Wolffsohn\u202fJS, Ben\u00edtez-Del-Castillo\u202fJ, Loya-Garc\u00eda\u202fD, Inomata\u202fT, Iyar\u202fG, Liang\u202fL, et\u202fal (2025) TFOS DEWS\u202fIII diagnostic methodology. Am J Ophthalmol Epub ahead of print. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.033","DOI":"10.1016\/j.ajo.2025.05.033"},{"issue":"9","key":"4205_CR7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jfo.2021.03.008","volume":"44","author":"H Lajmi","year":"2021","unstructured":"Lajmi H, Chelly Z, Choura R, Mansour KB, Hmaied W (2021) Relationship between OSDI score and biomicroscopic ocular surface damages in glaucomatous patients treated with preserved antiglaucomatous eye drops. J Fr Ophtalmol 44(9):1326\u20131331. https:\/\/doi.org\/10.1016\/j.jfo.2021.03.008","journal-title":"J Fr Ophtalmol"},{"issue":"2","key":"4205_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.18240\/ijo.2023.02.06","volume":"16","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang L, Zhou Y, Li Y, Wang W et al (2023) Effects of \u03b1-adrenergic agonists, prostaglandin analogues, and \u03b2-blockers on ocular surface disease in glaucoma treatment. Int J Ophthalmol 16(2):245\u2013258. https:\/\/doi.org\/10.18240\/ijo.2023.02.06","journal-title":"Int J Ophthalmol"},{"key":"4205_CR9","first-page":"850","volume-title":"Ophthalmology","year":"2020","unstructured":"Yanoff M, Duker JS (eds) (2020) Ophthalmology, 5th ed. Elsevier, Amsterdam, pp 850\u2013860","edition":"5th ed"},{"issue":"10","key":"4205_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s10792-018-0998-4","volume":"39","author":"A Guarnieri","year":"2019","unstructured":"Guarnieri A, Carnero E, Bleau AM, Alfonso-Bartolozzi B, Moreno-Monta\u00f1\u00e9s J (2019) Relationship between OSDI questionnaire and ocular surface changes in glaucomatous patients. Int Ophthalmol 39(10):2265\u20132271. https:\/\/doi.org\/10.1007\/s10792-018-0998-4","journal-title":"Int Ophthalmol"},{"issue":"10","key":"4205_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1089\/jop.2021.0071","volume":"37","author":"J-H Wu","year":"2021","unstructured":"Wu J-H, Wang T-H, Huang J-Y, Su C-C (2021) Ocular surface disease in glaucoma patients randomized to benzalkonium chloride-containing latanoprost and preservative-free bimatoprost. J Ocul Pharmacol Ther 37(10):564\u2013571. https:\/\/doi.org\/10.1089\/jop.2021.0071","journal-title":"J Ocul Pharmacol Ther"},{"key":"4205_CR12","unstructured":"Cirrus\u00ae 6000 HD-OCT system [Internet]. (2020) Dublin, CA: Carl Zeiss Meditec, Inc.; Available from: https:\/\/www.zeiss.com\/meditec\/en\/products\/optical-coherence-tomography-devices\/cirrus-6000-performance-oct\/specifications.html"},{"issue":"1 Suppl","key":"4205_CR13","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.035","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP et al (2021) Primary open-angle glaucoma preferred practice pattern. Ophthalmology 128(1 Suppl):P71-150. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.035","journal-title":"Ophthalmology"},{"issue":"3","key":"4205_CR14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/jcm12030828","volume":"12","author":"K Mercieca","year":"2023","unstructured":"Mercieca K, Figus M (2023) Advances in glaucoma surgery. J Clin Med 12(3):828. https:\/\/doi.org\/10.3390\/jcm12030828","journal-title":"J Clin Med"},{"key":"4205_CR15","unstructured":"American Academy of Ophthalmology. (2024) Basic and clinical science course\u2122 (BCSC). In: Section\u202f08: external disease and cornea. 7th ed. San Francisco (CA), AAO"},{"issue":"1","key":"4205_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1279-7","volume":"20","author":"A Guarnieri","year":"2020","unstructured":"Guarnieri A, Carnero E, Bleau AM, L\u00f3pez de Aguileta Casta\u00f1o N, Llorente Ortega M, Moreno-Monta\u00f1\u00e9s J (2020) Ocular surface analysis and automatic non-invasive assessment of tear film breakup location, extension and progression in patients with glaucoma. BMC Ophthalmol 20(1):12. https:\/\/doi.org\/10.1186\/s12886-019-1279-7","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"4205_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.exer.2009.07.014","volume":"89","author":"CJ Nien","year":"2009","unstructured":"Nien CJ, Paugh JR, Massei S, Wahlert AJ, Kao WW, Jester JV (2009) Age-related changes in the meibomian gland. Exp Eye Res 89(6):1021\u20131027. https:\/\/doi.org\/10.1016\/j.exer.2009.07.014","journal-title":"Exp Eye Res"},{"issue":"4","key":"4205_CR18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","volume":"52","author":"E Knop","year":"2011","unstructured":"Knop E, Knop N, Millar T, Obata H, Sullivan DA, International Workshop on Meibomian Gland Dysfunction (2011) The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 52(4):1938\u20131978. https:\/\/doi.org\/10.1167\/iovs.10-6997c","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"4205_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/ICO.0000000000001181","volume":"36","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kam WR, Liu Y, Chen X, Sullivan DA (2017) Influence of pilocarpine and timolol on human meibomian gland epithelial cells. Cornea 36(6):719\u2013724. https:\/\/doi.org\/10.1097\/ICO.0000000000001181","journal-title":"Cornea"},{"issue":"8","key":"4205_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/ICO.0000000000000838","volume":"35","author":"E Uzunosmanoglu","year":"2016","unstructured":"Uzunosmanoglu E, Mocan MC, Kocabeyoglu S, Karakaya J, Irkec M (2016) Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea 35(8):1112\u20131116. https:\/\/doi.org\/10.1097\/ICO.0000000000000838","journal-title":"Cornea"},{"issue":"1","key":"4205_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12886-021-02004-z","volume":"21","author":"M Sahlu","year":"2021","unstructured":"Sahlu M, Giorgis AT (2021) Dry eye disease among glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia. BMC Ophthalmol 21(1):328. https:\/\/doi.org\/10.1186\/s12886-021-02004-z","journal-title":"BMC Ophthalmol"},{"key":"4205_CR22","first-page":"97","volume-title":"Monographs in contact allergy","author":"AC Groot","year":"2021","unstructured":"Groot AC (2021) Brimonidine \u2013 an overview. In: de Groot AC (ed) Monographs in contact allergy. CRC Press, Boca Raton (FL), pp 97\u2013105"},{"issue":"1","key":"4205_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtos.2017.09.001","volume":"16","author":"EK McDennett","year":"2018","unstructured":"McDennett EK, Casey K, Basu S, Dana R (2018) Role of corneal nerves in ocular surface homeostasis and disease. Ocul Surf 16(1):31\u201342. https:\/\/doi.org\/10.1016\/j.jtos.2017.09.001","journal-title":"Ocul Surf"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04205-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04205-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:46:41Z","timestamp":1787302001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04205-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4205"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04205-5","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"339"}}